文献速递肝病

利福平用于胆汁淤积性瘙痒时肝毒性风险低:一项跨疾病队列研究

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2018-02-22

该回顾性队列研究纳入2012至2016年因胆汁淤积性瘙痒开始服用利福平的105例肝病患者,中位用药131天,5例(4.8%)发生利福平诱导性肝炎(中位70天),停药后均恢复,基线特征与肝炎发生无显著关联,作者认为约95%的处方是安全的。

要点

  • 105例患者中5例(4.8%)发生利福平诱导性肝炎,中位潜伏期70天。
  • 所有肝炎病例停药后均恢复,其中1例住院并接受糖皮质激素治疗。
  • 无个体或实验室基线特征与后续肝炎发生显著相关。

核心结论

  • 作者认为,鉴于利福平对部分胆汁淤积性瘙痒患者有效,可告知成人患者(包括黄疸患者)约95%的处方是安全的,发生肝炎时停药似乎有效,包括长潜伏期病例。

研究设计与样本

  • 回顾性队列研究,回顾2012至2016年因瘙痒开始服用利福平的门诊患者记录,排除后共纳入105例已确诊肝病并伴胆汁淤积性瘙痒的患者。

主要发现

  • 105例患者服用利福平的中位时间为131天;40例(38.1%)为男性,中位年龄44岁(IQR:32-57)。
  • 44例(41.9%)基线血清胆红素≥2×ULN,28例(26.7%)ALT≥3×ULN。
  • 5例(4.8%)发生利福平诱导性肝炎,中位时间为开始用药后70天(范围27-130天)。
  • 无个体或实验室基线特征与后续肝炎发生显著相关。
  • 所有肝炎病例停药后均恢复,其中1例住院并接受糖皮质激素治疗。

关键数值与推荐

  • 利福平诱导性肝炎定义为ALT升高至同时≥5×基线且≥5×ULN,或ALT升高至同时≥3×基线且≥3×ULN并伴血清胆红素升高至同时≥2×基线且≥2×ULN,且Roussel-Uclaf因果关系评估法评分对利福平因果关系为「可能」或「很可能」。

临床怎么用

  • 作者认为,可告知成人胆汁淤积性瘙痒患者(包括黄疸患者)约95%的利福平处方是安全的,发生肝炎时停药似乎有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of rifampicin for cholestatic pruritus is accompanied by concerns over safety, but the availability of real-world prescribing data is relatively limited. AIM: We sought to describe the rate and characteristics of rifampicin-induced hepatitis in a mixed aetiology cohort of patients with established liver disease and cholestatic pruritus. METHODS: Retrospective review of records for out-patients commenced on rifampicin for pruritus 2012-2016 inclusive. Rifampicin-induced hepatitis was recorded where alanine aminotransferase activity (ALT) increased to both ≥5 × baseline and ≥5 × upper limit of normal (ULN), or to both ≥3 × baseline and ≥3 × ULN with concurrent elevation in serum bilirubin to ≥2 × baseline and ≥2 × ULN, in addition to a Roussel-Uclaf Causality Assessment Method score of "probable" or "highly probable" for rifampicin causality. RESULTS: After exclusions, we reviewed 105 patients who took rifampicin for a median of 131 days. Most had primary biliary cholangitis or primary sclerosing cholangitis; 40 (38.1%) were men and median age was 44 years (IQR: 32-57). 44 (41.9%) patients had baseline serum bilirubin ≥2 × ULN and 28 (26.7%) ALT ≥3 × ULN. 5 (4.8%) developed rifampicin-induced hepatitis at a median of 70(range 27-130) days after drug initiation. No individual or laboratory baseline characteristics were significantly associated with subsequent development of hepatitis. All cases of hepatitis recovered after drug cessation, although one patient was hospitalised and received corticosteroids. CONCLUSIONS: Given the efficacy of rifampicin for an important sub-group of those with cholestatic pruritus, adult patients, including those with jaundice, can be counselled that 95% of prescriptions are safe, and where hepatitis occurs, including at long latency, drug cessation appears effective.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Webb GJ, Rahman SR, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther. 2018. PMID: 29468705. doi:10.1111/apt.14579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。